Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $20.40, for a total value of $66,300.00. Following the transaction, the chief financial officer owned 23,000 shares in the company, valued at $469,200. This represents a 12.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, August 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.63, for a total value of $67,047.50.
• On Monday, July 28th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.46, for a total value of $66,495.00.
• On Thursday, July 10th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.66, for a total value of $22,660.00.

Enliven Therapeutics Stock Up 0.5%

NASDAQ:ELVN opened at $19.92 on Friday. The stock’s 50 day moving average price is $19.66 and its 200 day moving average price is $19.60. The company has a market capitalization of $1.18 billion, a PE ratio of -9.96 and a beta of 0.85. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. As a group, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ELVN has been the topic of several analyst reports. Robert W. Baird lifted their target price on Enliven Therapeutics from $40.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, June 16th. The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a research note on Monday, June 16th. They issued a “buy” rating and a $37.00 target price on the stock. Finally, HC Wainwright lifted their target price on Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, July 2nd. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $41.20.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently modified their holdings of the business. GAMMA Investing LLC lifted its holdings in shares of Enliven Therapeutics by 3,058.1% in the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock valued at $53,000 after buying an additional 2,630 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Enliven Therapeutics in the 1st quarter valued at approximately $60,000. BNP Paribas Financial Markets lifted its holdings in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Enliven Therapeutics by 194.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after buying an additional 3,490 shares during the period. Finally, KLP Kapitalforvaltning AS lifted its holdings in shares of Enliven Therapeutics by 58.1% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after buying an additional 2,500 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.